Tag: medytox

medytox

Latest News

미국 ITC 위원회는 16일(현지시간) 대웅제약의 보툴리눔 톡신 제제 '나보타'(미국 제품명 주보)가 불공정 무역관행 제재 규정을 위반한 제품이라 판단해 21개월간 미국 내 수입 금지를 명령하는 최종판결을 내렸다. 지난해 1월 보툴리눔 톡신 제제 '메디톡신'의 제조사 메디톡스는 대웅제약이 자사의 균주와 제조공정 기술문서 등을 훔쳐 갔다고 보고 ITC에 영업비밀 침해 혐의로 공식 제소했다. 사진은 17일 서울 강남구에 위치한 메디톡스 빌딩과 대웅제약 본사의 모습. 2020.12.17 ondol@yna.co.kr/2020-12-17 15:22:59/

Medytox-Daewoong Botox feud flares anew with 10-fold damages claim

Medytox has raised its damages claim tenfold against Daewoong Pharmaceutical as their nine-year dispute over botulinum toxin technology continues in Korean courts.

2026.9.7

The representative toxin products of Medytox, from left, Meditoxin, Coretox, and Innotox. [MEDYTOX]

Medytox tightens its hold on the Middle East’s beauty boom

Korean biopharmaceutical company Medytox is expanding into the Middle East, a fast-growing pharmaceutical market often referred to as a "Pharmerging" — a blend of "pharmacy" and "emerging."

2025.2.17

Most popular

Hugel's botulax botulinum toxin products [HUGEL]

Preliminary U.S. trade decision favors Hugel over Medytox in Botox-related case

Kosdaq-listed Hugel prevailed over Medytox in a preliminary decision by the U.S. International Trade Commission in a dispute over a Botox-related product.

2024.6.11

[NEWS ANALYSIS] Second Battle of the Botoxes breaks out in Korea

Botulinum toxin is at the center of another legal battle as Medytox accused Hugel of misappropriation of trade secrets.

2022.4.13

Medytox, Daewoong benefit as Botox deal nullifies ITC ban

After emerging victorious in a protracted trade secrets dispute last year, Medytox has received billions of dollars in license fees and royalty fees and bought a stake in the U.S. botulinum toxin maker Evolus, becoming its second largest stakeholder.

2021.2.22

Medytox to fight ministry's ban on Innotox in court

Medytox is set to initiate another legal battle against the Ministry of Food and Drug Safety, as the company announced Wednesday it will challenge a sales and production ban issued against its Innotox “Botox” product.

2020.12.23

U.S. ITC ends 'Botox brawl' in Medytox's favor, but reduces penalty

After a two-year investigation, the U.S. International Trade Commission has made a final determination in favor of Medytox in its high-profile “Botox brawl” with Daewoong Pharmaceutical.

2020.12.17

Medytox botches Botox labeling but cites wrinkle in law

The Ministry of Food and Drug Safety ordered Medytox to recall and destroy 50-unit, 100-unit, 150-unit and 200-unit dosages of Meditoxin, Medytox’s bestselling botulinum toxin, citing violations of the Pharmaceutical Affairs Act.

2020.10.20

Daewoong Pharmaceutical's Nabota. [DAEWOONG PHARMACEUTICAL]

ITC agrees to review its decision in Botox dispute

The Botox war between Medytox and Daewoong Pharmaceutical has taken an unexpected turn as the U.S. International Trade Commission (ITC) decided to partially review its initial determination in favor of Medytox.

2020.9.22

Medytox wins Botox face-off, but there's a wrinkle

The U.S. International Trade Commission (ITC) made an initial determination Monday. It concluded that Daewoong’s botulinum toxin product, Nabota, was made with bacteria and intellectual property stolen from Medytox.

2020.7.7